Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Q1 Revenues Rise 3 Percent

Premium

Thermo Fisher Scientific this week reported first-quarter revenue growth of three percent year-over-year, with revenues for its Analytical Technologies segment, which includes the company's life sciences mass spectrometry business, climbing 9 percent to $1.18 billion from $1.08 billion a year ago.

During a conference call after the release of the company's results, President and CEO Marc Casper said Thermo's clinical diagnostics business posted double-digit growth in the quarter and highlighted the company's Brahms sepsis biomarker assay as particularly "strongly performing."

He also touched on the company's acquisition of chromatography firm Dionex (PM 12/17/2010), noting that the European Commission is reviewing the deal and it is expected to close in mid-May.

For the first quarter, Thermo Fisher posted net income of $252.2 million, or $.64 per share, up 9 percent from $232.3 million, or $.56 per share, a year ago. On an adjusted basis, EPS was $.92, compared to $.82 a year ago, beating Wall Street estimates of $.88.

The company increased its R&D spending to $74.8 million, up 13 percent from $66.1 million a year ago. Its SG&A costs increased 4 percent to $606.7 million from $584 million a year ago.

As of April 2, Thermo Fisher had $2.79 billion in cash and cash equivalents.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.